380 diabetic patients with hyperlipidaemia and undergoing treatment with sulphonylureas or insulin were given 200 mg bezafibrate t.i.d for 3 months after a control period of 4 weeks. After cessation of treatment a follow-up examination was performed a further 4 weeks later. 194 treatment centres took part in the investigation. Total cholesterol fell by 17%, triglycerides by 36% and HDL-cholesterol rose by 15% during the treatment period. In addition, a glucose-lowering effect was seen which led to a definite improvement in the control of diabetes both with glibenclamide and with insulin. The degree of glucose reduction was most marked in moderately or poorly controlled diabetics. There was no correlation between the triglyceride reduction and the glucose reduction. After cessation of bezafibrate treatment the cholesterol, triglyceride and fasting glucose increased again and the HDL-cholesterol diminished. However, they did not reach pretreatment values. Bezafibrate was well tolerated, hypoglycaemia or hypoglycaemic reactions were not observed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.